Standard Contracts
22,225,000 Shares of Common Stock LARIMAR THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 14th, 2022 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • New York
Larimar Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 22,225,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 3,333,750 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters, solely to cover over-allotments, as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
